This article is more than 5 years old. Information may no longer be current.
Antimicrobial barrier caps linked with lower catheter-related bloodstream infection rate in patients on hemodialysis
Click Here to Manage Email Alerts
Use of ClearGuard HD antimicrobial barrier caps, manufactured by Pursuit Vascular Inc., was associated with a significantly lower rate of catheter-related bloodstream infections among patients on hemodialysis using central venous catheters when compared with Tego connectors plus Curos caps, according to a study in the Journal of the American Society of Nephrology.
According to a company press release, the 13-month, prospective, multicenter, cluster-randomized trial included 1,671 patients who accrued approximately 183,000 treatment days at 40 dialysis centers across the United States. Participating centers were randomized to either treat patients using the ClearGuard HD Antimicrobial Barrier Cap or Tego connector in combination with Curos cap.
The primary outcome of the study was the number of positive blood cultures as an indicator of bloodstream infection (BSI) rate. The study demonstrated that use of ClearGuard HD caps resulted in a 63% lower BSI rate vs. use of Tego in combination with Curos. Additional exploratory analyses were performed which demonstrated that ClearGuard HD caps were superior to Tego in combination with Curos for reducing BSI by 63% to 82% across all nine analyses.
“This study’s primary analysis, along with the exploratory analyses, demonstrated that in a real-world hemodialysis setting, use of ClearGuard was superior to use of Tego [plus] Curos at reducing [positive blood cultures] PBCs, [catheter-related bloodstream infection] CRBSI, [central line-associated bloodstream infections] CLABSI, gram-positive infections, gram-negative infections and IV antibiotic starts related to PBCs in patients undergoing hemodialysis using [central venous catheters] CVCs,” the researchers wrote.
Reference:
www.clearguardhd.com/includes/Second_Major_Study_Demonstrates_Superiority_of_ClearGuard_HD_Caps.pdf
Disclosures: Brunelli reports he is an employee of DaVita Clinical Research. Please see the study for all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts